Eupraxia Pharmac SEC Filings

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, reported changes to its executive leadership and operating structure to support upcoming clinical and commercial milestones. Dr. Jeff Millard has joined as Executive Vice President, Technical Operations effective July 13, 2026, bringing nearly 25 years of experience in technical operations, CMC and regulatory strategy. Dr. Alex Therien, who joined in November 2025, will lead Research & Development as Executive Vice President, Research & Development, with responsibility for portfolio expansion.

The company has transitioned operations from Victoria to Vancouver and Seattle, with key clinical, manufacturing and commercial leaders, including the CEO, based in Seattle to support growing clinical operations. As part of this shift, Amanda Malone, based in Victoria, stepped down as Chief Scientific and Operating Officer effective July 10, 2026. Eupraxia is preparing for a Q4 2026 interim data release from its RESOLVE Phase 1b/2 trial of EP-104GI in Eosinophilic Esophagitis and is planning for potential Phase 3 development, regulatory, manufacturing and commercialization activities. The company also highlights prior Phase 2b SPRINGBOARD trial results for EP-104IAR in knee osteoarthritis, where the study met its primary endpoint and three of four secondary endpoints, and notes a broader pipeline of long-acting formulations using its Diffusphere™ drug delivery platform.

Eupraxia Pharmaceuticals Inc. filed a Form 6-K to share a press release announcing three new appointments to its Board of Directors: Robert Bazemore, Amy Pott and Dr. Helen Thackray. These directors bring deep experience in late-stage drug development, commercialization and global product launches across oncology, rare disease and gene therapy.

The company highlights its proprietary Diffusphere™ technology for localized, extended-release drug delivery and provides an update that EP-104GI is in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis, while EP-104IAR met the primary endpoint and most secondary endpoints in a Phase 2b knee osteoarthritis trial.

Eupraxia Pharmaceuticals Inc. reported the results of its Annual General Meeting held on June 18, 2026. Shareholders approved setting the board size at seven directors and elected all seven management nominees, each receiving strong support, with most candidates above 97% of votes cast in favour.

Shareholders also re-appointed KPMG LLP as the Company’s auditor for the ensuing year and authorized the board to fix the auditor’s pay, with more than 99% of votes cast in favour. These outcomes maintain board continuity and the existing audit relationship for the next year.

Eupraxia Pharmaceuticals Inc. is calling a virtual-only annual general meeting for shareholders on June 18, 2026, with a May 8, 2026 record date and 65,313,147 common shares entitled to one vote each.

Shareholders are being asked to set the Board size at seven, elect five incumbent directors plus two new nominees, and reappoint KPMG LLP as auditor with fees set by the Board. The circular details Eupraxia’s governance structure, committee composition, diversity policy, and a rolling Omnibus Incentive Plan that allows equity awards up to 18.5% of outstanding shares. It also outlines 2026 executive compensation targets, including base salaries and bonus opportunities tied to corporate and individual performance.

Eupraxia Pharmaceuticals Inc. submitted a Form 6-K as a foreign private issuer to confirm an administrative step related to its upcoming shareholder matters. The company’s transfer agent, TSX Trust Company, states that proxy-related materials were mailed on May 27, 2026 to Registered Securityholders and ESP Holders. This filing simply documents that the required proxy documents have been distributed.

Eupraxia Pharmaceuticals Inc. filed a Form 6-K to share that its management team will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 3, 2026, from 5:30PM to 6:00PM in New York, with 1x1 investor meetings on June 3 and 4.

Eupraxia is a clinical-stage biotechnology company developing locally delivered, extended-release treatments using its proprietary Diffusphere™ micro-sphere technology. Its pipeline includes EP-104GI in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis and EP-104IAR, which met the primary endpoint in a Phase 2b knee osteoarthritis pain trial.

EUPRAXIA PHARMACEUTICALS INC. ownership disclosure: Manchester Management entities and associated individuals report beneficial holdings in Common Shares as of 03/31/2026.

Manchester Management Company, LLC and Manchester Management PR, LLC each report 3,830,869 shares (7.4%); Manchester Explorer, L.P. reports 3,707,942 shares (7.1%). James E. Besser reports 3,969,162 shares (7.6%) and Morgan C. Frank reports 4,015,248 shares (7.7%).

Eupraxia Pharmaceuticals Inc. reported a larger net loss for the three months ended March 31, 2026 as it accelerated spending on its EP-104 pipeline. Net loss was $12.7 million compared with $6.8 million a year earlier, driven mainly by higher research and development and corporate costs.

Research and development expenses more than doubled to $11.2 million, reflecting expanded clinical activity in eosinophilic esophagitis and related programs, while general and administrative expenses rose to $4.8 million. To support this growth, Eupraxia completed a February 2026 equity financing, raising roughly $63.2 million gross through common shares and pre-funded warrants.

Despite the higher loss, the company ended the quarter with a substantial cash position: cash and cash equivalents of $58.5 million and short-term investments of $80.4 million, backing ongoing Phase 1b/2 work in EP-104GI and strategic options for EP-104IAR. Management continues to emphasize the need for future financings or partnerships to fund later-stage trials and potential commercialization.

Eupraxia Pharmaceuticals reported new tissue-based results from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis (EoE). Using the EoE Histology Scoring System (EoEHSS), inflammation sub scores improved in all reported cohorts at 12 weeks (n=31) and 36 weeks (n=27).

Tissue architecture and fibrosis sub scores also improved across most cohorts. At the highest dose cohort, grade and stage improvements in inflammatory scores exceeded 90%, and architectural/fibrotic scores improved by more than 83% at both 12 and 36 weeks. These findings align with earlier symptom and endoscopic (EREFS) improvements.

The open-label dose-escalation portion of RESOLVE follows patients up to 24 or 52 weeks, depending on cohort. A randomized, placebo-controlled Phase 2b part of RESOLVE is now recruiting 120 mg and 160 mg doses of EP-104GI, with top-line data expected in Q4 2026.